Giovanni Monteleone

List of Publications by Year
in descending order

290	18,173	13332	18944
papers	citations	70 h-index	123 g-index

294	294	294	21021
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ultrasonography Tight Control and Monitoring in Crohnâ€™s Disease During Different Biological Therapies: A Multicenter Study. Clinical Gastroenterology and Hepatology, 2022, 20, e711-e722.	2.4	41
2	The Deubiquitinating Enzyme OTUD5 Sustains Inflammatory Cytokine Response in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 122-132.	0.6	12
3	GATA6 Deficiency Leads to Epithelial Barrier Dysfunction and Enhances Susceptibility to Gut Inflammation. Journal of Crohn's and Colitis, 2022, 16, 301-311.	0.6	15
4	Poorly Cohesive Carcinoma of the Nonampullary Small Intestine. American Journal of Surgical Pathology, 2022, 46, 498-508.	2.1	7
5	Intestinal Taxa Abundance and Diversity in Inflammatory Bowel Disease Patients: An Analysis including Covariates and Confounders. Nutrients, 2022, 14, 260.	1.7	21
6	Implication of Intestinal Barrier Dysfunction in Gut Dysbiosis and Diseases. Biomedicines, 2022, 10, 289.	1.4	81
7	Difficult Biliary Stones: A Comprehensive Review of New and Old Lithotripsy Techniques. Medicina (Lithuania), 2022, 58, 120.	0.8	19
8	Endoscopic Ultrasound Plus Endoscopic Retrograde Cholangiopancreatography Based Tissue Sampling for Diagnosis of Proximal and Distal Biliary Stenosis Due to Cholangiocarcinoma: Results from a Retrospective Single-Center Study. Cancers, 2022, 14, 1730.	1.7	3
9	Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment. Nucleic Acid Therapeutics, 2022, 32, 312-320.	2.0	8
10	Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab. Journal of Clinical Medicine, 2022, 11, 1679.	1.0	7
11	Interleukin-34 Mediates Cross-Talk Between Stromal Cells and Immune Cells in the Gut. Frontiers in Immunology, 2022, 13, 873332.	2.2	4
12	EUS-FNA/FNB AND ERCP IN THE DIAGNOSTIC WORK-UP OF BILIARY STENOSIS: A RETROSPECTIVE STUDY. Endoscopy, 2022, 54, .	1.0	0
13	Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?. Molecular Diagnosis and Therapy, 2022, 26, 477-481.	1.6	8
14	Idiopathic acute pancreatitis: a single-center investigation of clinical and biochemical features. Internal and Emergency Medicine, 2021, 16, 93-99.	1.0	0
15	The Fragile X Mental Retardation Protein Regulates RIPK1 and Colorectal Cancer Resistance to Necroptosis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 639-658.	2.3	21
16	Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors. Scandinavian Journal of Gastroenterology, 2021, 56, 498-504.	0.6	8
17	Clinical care pathway program versus open-access system: a study on appropriateness, quality, and efficiency in the delivery of colonoscopy in the colorectal cancer. Internal and Emergency Medicine, 2021, 16, 1197-1206.	1.0	3
18	Low Frequency of Acute Pancreatitis in Hospitalized COVID-19 Patients. Pancreas, 2021, 50, 393-398.	0.5	15

#	Article	IF	Citations
19	Metalloproteinases in Inflammatory Bowel Diseases. Journal of Inflammation Research, 2021, Volume 14, 1029-1041.	1.6	29
20	Natural History of Ulcerative Colitis with Coexistent Colonic Diverticulosis. Journal of Clinical Medicine, 2021, 10, 1192.	1.0	1
21	A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohnâ€™s Disease: A Phase II, Open-Label Study. BioDrugs, 2021, 35, 325-336.	2.2	13
22	Precision Medicine in Inflammatory Bowel Diseases. Frontiers in Pharmacology, 2021, 12, 653924.	1.6	10
23	Involvement of Smad7 in Inflammatory Diseases of the Gut and Colon Cancer. International Journal of Molecular Sciences, 2021, 22, 3922.	1.8	11
24	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
25	Multiple hepatic and brain abscesses caused by Parvimonas micra: A case report and literature review. Anaerobe, 2021, 69, 102366.	1.0	7
26	Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases. European Journal of Gastroenterology and Hepatology, 2021, 33, 977-982.	0.8	4
27	Efficacy of hemostatic powders as monotherapy or rescue therapy in gastrointestinal bleeding related to neoplastic or non-neoplastic lesions. Scandinavian Journal of Gastroenterology, 2021, 56, 1506-1513.	0.6	5
28	Interleukin-34 promotes tumorigenic signals for colon cancer cells. Cell Death Discovery, 2021, 7, 245.	2.0	7
29	Role of TGF-Beta and Smad7 in Gut Inflammation, Fibrosis and Cancer. Biomolecules, 2021, 11, 17.	1.8	47
30	Tips and tricks for the diagnosis and management of biliary stenosis-state of the art review. World Journal of Gastrointestinal Endoscopy, 2021, 13, 473-490.	0.4	7
31	Lipidomics and metabolomics signatures of SARS-CoV-2 mediators/receptors in peripheral leukocytes, jejunum and colon. Computational and Structural Biotechnology Journal, 2021, 19, 6080-6089.	1.9	7
32	Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids. Journal of Clinical Medicine, 2021, 10, 5413.	1.0	1
33	Long COVID in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2021, 10, 5575.	1.0	6
34	Contrastâ€“enhanced endoscopic ultrasound diagnosis of the intraductal papillary mucinous neoplasm. Clinical Journal of Gastroenterology, 2020, 13, 120-126.	0.4	1
35	Cadherin-11 Is a Regulator of Intestinal Fibrosis. Journal of Crohn's and Colitis, 2020, 14, 406-417.	0.6	24
36	Response Assessed by Ultrasonography as Target of Biological Treatment for Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 2030-2037.	2.4	39

#	Article	IF	Citations
37	Interrogating host immunity to predict treatment response in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 9-20.	8.2	76
38	Interleukin-34 Enhances the Tumor Promoting Function of Colorectal Cancer-Associated Fibroblasts. Cancers, 2020, 12, 3537.	1.7	18
39	Macrophages produce and functionally respond to interleukin-34 in colon cancer. Cell Death Discovery, 2020, 6, 117.	2.0	13
40	Onset of ulcerative colitis during SARS-CoV-2 infection. Digestive and Liver Disease, 2020, 52, 1228-1229.	0.4	17
41	P196 High frequency of undiagnosed mental illness in inflammatory bowel diseases. Journal of Crohn's and Colitis, 2020, 14, S236-S237.	0.6	0
42	High Smad7 in the early post-operative recurrence of Crohnâ€™s disease. Journal of Translational Medicine, 2020, 18, 395.	1.8	7
43	A Novel Smad7 Genetic Variant Mapping on the Genomic Region Targeted by Mongersen Is Associated with Crohnâ€™s Disease. Biomedicines, 2020, 8, 234.	1.4	4
44	Viruses in Cancers of the Digestive System: Active Contributors or Idle Bystanders?. International Journal of Molecular Sciences, 2020, 21, 8133.	1.8	11
45	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. Autoimmunity Reviews, 2020, 19, 102574.	2.5	32
46	High Frequency of Undiagnosed Psychiatric Disorders in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2020, 9, 1387.	1.0	18
47	Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK)Âlnhibitors . Clinical and Experimental Gastroenterology, 2020, Volume 13, 131-139.	1.0	20
48	Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells. Cancers, 2020, 12, 1314.	1.7	13
49	The impact of COVID-19 pandemic in the colorectal cancer prevention. International Journal of Colorectal Disease, 2020, 35, 1951-1954.	1.0	76
50	Association Between Celiac Disease and Cancer. International Journal of Molecular Sciences, 2020, 21, 4155.	1.8	33
51	No effect of a liquid diet in the management of patients with stricturing Crohnâ€™s disease. International Journal of Colorectal Disease, 2020, 35, 1881-1885.	1.0	2
52	Impact of surgery on quality of life in Crohnâ€™s disease: short- and mid-term follow-up. Updates in Surgery, 2020, 72, 773-780.	0.9	8
53	Minimal Open Access Ileocolic Resection in Complicated Crohnâ€™s Disease of the Terminal Ileum. Gastroenterology Research and Practice, 2020, 2020, 1-6.	0.7	4
54	TGF-Î² activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases. Pharmacological Research, 2020, 155, 104757.	3.1	7

#	Article	IF	Citations
55	Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection?. Journal of Crohn's and Colitis, 2020, 14, 1334-1336.	0.6	162
56	Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment. Molecular Metabolism, 2020, 36, 100976.	3.0	46
57	Low frequency of COVID-19 in inflammatory bowel diseases. Digestive and Liver Disease, 2020, 52, 1234-1235.	0.4	12
58	Feasibility and cost effectiveness of ambulatory laparoscopic cholecystectomy. A retrospective cohort study. Annals of Medicine and Surgery, 2020, 55, 56-61.	0.5	15
59	Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases . Biologics: Targets and Therapy, 2020, Volume 14, 47-51.	3.0	2
60	Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2020, 9, 2126.	1.0	3
61	mTOR sustains inflammatory response in celiac disease. Scientific Reports, 2020, 10, 10798.	1.6	17
62	Effect of chemical modulation of toll-like receptor 4 in an animal model of ulcerative colitis. European Journal of Clinical Pharmacology, 2020, 76, 409-418.	0.8	12
63	Role of Interleukin-34 in Cancer. Cancers, 2020, 12, 252.	1.7	29
64	Endoscopic retrieval through a lumen-apposing metal stent of a biflanged metal stent that had been released into a peripancreatic fluid collection. Endoscopy, 2020, 52, E275-E276.	1.0	1
65	Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. Journal of Clinical Medicine, 2020, 9, 385.	1.0	5
66	Preventing COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatology, The, 2020, 2, e255-e256.	2.2	85
67	Interleukin-34 Stimulates Gut Fibroblasts to Produce Collagen Synthesis. Journal of Crohn's and Colitis, 2020, 14, 1436-1445.	0.6	30
68	Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2020, 11, 585732.	1.6	4
69	Extra-intestinal manifestations of inflammatory bowel diseases. Pharmacological Research, 2020, 161, 105206.	3.1	22
70	Albendazole negatively regulates keratinocyte proliferation. Clinical Science, 2020, 134, 907-920.	1.8	9
71	Malignant gastric outlet obstruction: Which is the best therapeutic option?. World Journal of Gastroenterology, 2020, 26, 1847-1860.	1.4	59
72	Expression of Receptors for SARS-CoV-2 in the Gut of Patients with Inflammatory Bowel Disease. Gut and Liver, 2020, 14, 530-531.	1.4	7

#	Article	IF	Citations
73	ENDOSCOPIC RETRIEVAL OF A BI-FLANGED METAL STENT RELEASED INTO A PERIPANCREATIC FLUID COLLECTION THROUGH A LUMEN-APPOSING METAL STENT. Endoscopy, 2020, 52, .	1.0	0
74	Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease. Frontiers in Microbiology, 2019, 10, 1655.	1.5	146
75	Inflammatory cytokines: from discoveries to therapies in IBD. Expert Opinion on Biological Therapy, 2019, 19, 1207-1217.	1.4	104
76	Induction of endoplasmic reticulum stress and inhibition of colon carcinogenesis by the anti-helmintic drug rafoxanide. Cancer Letters, 2019, 462, 1-11.	3.2	13
77	Progranulin sustains <scp>STAT</scp>3 hyperâ€activation and oncogenic function in colorectal cancer cells. Molecular Oncology, 2019, 13, 2142-2159.	2.1	17
78	Impact of Food Additives on Gut Homeostasis. Nutrients, 2019, 11, 2334.	1.7	75
79	Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis. Frontiers in Immunology, 2019, 10, 2158.	2.2	42
80	Smad7 and Colorectal Carcinogenesis: A Double-Edged Sword. Cancers, 2019, 11, 612.	1.7	17
81	Oligonucleotidesâ€"A Novel Promising Therapeutic Option for IBD. Frontiers in Pharmacology, 2019, 10, 314.	1.6	24
82	Idiopathic acute pancreatitis: a review on etiology and diagnostic work-up. Clinical Journal of Gastroenterology, 2019, 12, 511-524.	0.4	28
83	Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease. Frontiers in Pharmacology, 2019, 10, 305.	1.6	74
84	Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. Inflammatory Bowel Diseases, 2019, 25, 1805-1812.	0.9	30
85	Protective Effects of Aryl Hydrocarbon Receptor Signaling in Celiac Disease Mucosa and in Poly I:C-Induced Small Intestinal Atrophy Mouse Model. Frontiers in Immunology, 2019, 10, 91.	2.2	15
86	The Food Additive Maltodextrin Promotes Endoplasmic Reticulum Stressâ€"Driven Mucus Depletion and Exacerbates Intestinal Inflammation. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 457-473.	2.3	84
87	Lumen-apposing metal stents for malignant biliary obstruction: Is this the ultimate horizon of our experience?. World Journal of Gastroenterology, 2019, 25, 3857-3869.	1.4	23
88	Knockdown of Smad7 With a Specific Antisense Oligonucleotide Attenuates Colitis and Colitis-Driven Colonic Fibrosis in Mice. Inflammatory Bowel Diseases, 2018, 24, 1213-1224.	0.9	22
89	Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohnâ€™s Disease: An International Multicenter Study. Inflammatory Bowel Diseases, 2018, 24, 2001-2006.	0.9	39
90	Metformin inhibits inflammatory signals in the gut by controlling AMPK and p38 MAP kinase activation. Clinical Science, 2018, 132, 1155-1168.	1.8	53

#	Article	IF	Citations
91	Targeting IL-23 in Crohnâ€™s disease. Expert Review of Clinical Immunology, 2018, 14, 907-913.	1.3	12
92	Reciprocal Regulation Between Smad7 and Sirt1 in the Gut. Frontiers in Immunology, 2018, 9, 1854.	2.2	13
93	Transforming Growth Factor-Î²1/Smad7 in Intestinal Immunity, Inflammation, and Cancer. Frontiers in Immunology, 2018, 9, 1407.	2.2	62
94	STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment. International Journal of Molecular Sciences, 2018, 19, 1787.	1.8	106
95	RORÎ³t-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells. Cancer Immunology Research, 2018, 6, 1082-1092.	1.6	35
96	<scp>PIK</scp>3<scp>CA</scp> c.3140A>G mutation in a patient with suspected Proteus Syndrome: a case report. Clinical Case Reports (discontinued), 2018, 6, 1358-1363.	0.2	4
97	Advances in understanding the role of cytokines in inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2018, 12, 907-915.	1.4	51
98	Oligonucleotide-Based Therapies for Inflammatory Bowel Disease. BioDrugs, 2018, 32, 331-338.	2.2	12
99	High SMAD7 and p-SMAD2,3 expression is associated with environmental enteropathy in children. PLoS Neglected Tropical Diseases, 2018, 12, e0006224.	1.3	12
100	Inflammatory bowel disease: new therapies from antisense oligonucleotides. Annals of Medicine, 2018, 50, 361-370.	1.5	14
101	Interleukin-34 sustains pro-tumorigenic signals in colon cancer tissue. Oncotarget, 2018, 9, 3432-3445.	0.8	57
102	SAT0266â€…Use of conventional synthetic dmards and biological dmards in patients with enteropathic spondyloarthritis: a combined gastro-rheumatological approach. , 2018, , .		0
103	Internal shoulder impingement in overhead athletes: an ultrasound imaging proposal. Ultrasonography, 2018, 37, 275-276.	1.0	1
104	Inhibiting Oxidative Phosphorylation In Vivo Restrains Th17 Effector Responses and Ameliorates Murine Colitis. Journal of Immunology, 2017, 198, 2735-2746.	0.4	56
105	Smad7 positively regulates keratinocyte proliferation in psoriasis. British Journal of Dermatology, 2017, 177, 1633-1643.	1.4	17
106	The safety of non-biological treatments in Ulcerative Colitis. Expert Opinion on Drug Safety, 2017, 16, 779-789.	1.0	29
107	Smad7 knockdown activates protein kinase RNA-associated eIF2Î± pathway leading to colon cancer cell death. Cell Death and Disease, 2017, 8, e2681-e2681.	2.7	20
108	Immunomodulatory properties of Olea europaea leaf extract in intestinal inflammation. Molecular Nutrition and Food Research, 2017, 61, 1601066.	1.5	48

#	Article	IF	Citations
109	High Smad7 sustains inflammatory cytokine response in refractory coeliac disease. Immunology, 2017, 150, 356-363.	2.0	16
110	Sodium chlorideâ€“enriched Diet Enhanced Inflammatory Cytokine Production and Exacerbated Experimental Colitis in Mice. Journal of Crohn's and Colitis, 2017, 11, 237-245.	0.6	80
111	Interleukin-17 A-E. , 2017, , 549-572.		2
112	P332 Treat to target in Crohn's disease: ultrasonographic response is associated with better outcomes. Journal of Crohn's and Colitis, 2017, 11, S246-S246.	0.6	0
113	Smad7 as a Target for Immunomodulation Strategy in Inflammatory Bowel Diseases. Immunome Research, 2017, 13, .	0.1	0
114	Celiac Disease-Related Inflammation Is Marked by Reduction of Nkp44/Nkp46-Double Positive Natural Killer Cells. PLoS ONE, 2016, 11, e0155103.	1.1	20
115	A Role for Timp3 in Microbiota-Driven Hepatic Steatosis and Metabolic Dysfunction. Cell Reports, 2016, 16, 731-743.	2.9	18
116	Aryl hydrocarbon receptorâ€driven signals inhibit collagen synthesis in the gut. European Journal of Immunology, 2016, 46, 1047-1057.	1.6	38
117	Therapy implications for the role of IL-21 in lupus. Expert Review of Clinical Immunology, 2016, 12, 487-488.	1.3	0
118	Metagenomics Reveals Dysbiosis and a Potentially Pathogenic N. flavescens Strain in Duodenum of Adult Celiac Patients. American Journal of Gastroenterology, 2016, 111, 879-890.	0.2	128
119	Smad7 Knockdown Restores Aryl Hydrocarbon Receptor-mediated Protective Signals in the Gut. Journal of Crohn's and Colitis, 2016, 10, 670-677.	0.6	16
120	Tofacitinib for the treatment of ulcerative colitis. Expert Opinion on Investigational Drugs, 2016, 25, 991-997.	1.9	15
121	Sphingosine-1-phosphate receptor: a novel therapeutic target in ulcerative colitis. Expert Review of Clinical Immunology, 2016, 12, 1137-1139.	1.3	7
122	Impact of patient characteristics on the clinical efficacy of mongersen (GEDâ€0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 717-724.	1.9	35
123	The gutâ€skin axis in health and disease: A paradigm with therapeutic implications. BioEssays, 2016, 38, 1167-1176.	1.2	264
124	No Change in the Mucosal Gut Microbiome is Associated With Celiac Disease-Specific Microbiome Alteration in Adult Patients. American Journal of Gastroenterology, 2016, 111, 1659-1661.	0.2	18
125	CCL20 Is Negatively Regulated by TGF-Î²1 in Intestinal Epithelial Cells and Reduced in Crohnâ€™s Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide. Journal of Crohn's and Colitis, 2016, 11, jjw191.	0.6	26
126	Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohnâ€™s disease. Therapeutic Advances in Gastroenterology, 2016, 9, 527-532.	1.4	37

#	Article	IF	Citations
127	Interleukin-34 Induces Cc-chemokine Ligand 20 in Gut Epithelial Cells. Journal of Crohn's and Colitis, 2016, 10, 87-94.	0.6	46
128	Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases. Current Drug Metabolism, 2016, 17, 303-306.	0.7	12
129	Entrapment of the sciatic nerve at the linea aspera: A case report and literature review. , 2016, 7, 89.		1
130	Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease. Clinical Science, 2015, 129, 1107-1113.	1.8	24
131	The TGF-Î²/Smad System in IBD Pathogenesis. Inflammatory Bowel Diseases, 2015, 21, 2921-2925.	0.9	50
132	The IL-12/23/STAT Axis as a Therapeutic Target in Inflammatory Bowel Disease: Mechanisms and Evidence in Man. Digestive Diseases, 2015, 33, 113-119.	0.8	15
133	Interleukin-34 sustains inflammatory pathways in the gut. Clinical Science, 2015, 129, 271-280.	1.8	57
134	Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohnâ€™s Disease. New England Journal of Medicine, 2015, 372, 1104-1113.	13.9	366
135	Antisense Approach to Inflammatory Bowel Disease: Prospects and Challenges. Drugs, 2015, 75, 723-730.	4.9	24
136	Th17-type cytokines, IL-6 and TNF-Î± synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene, 2015, 34, 3493-3503.	2.6	426
137	TNF-Î± Producing Innate Lymphoid Cells (ILCs) Are Increased in Active Celiac Disease and Contribute to Promote Intestinal Atrophy in Mice. PLoS ONE, 2015, 10, e0126291.	1.1	61
138	Peritoneal expression of matrilysin helps identify early post-operative recurrence of colorectal cancer. Oncotarget, 2015, 6, 13402-13415.	0.8	21
139	Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis. Oncotarget, 2015, 6, 9908-9923.	0.8	47
140	Impairment of ghrelin synthesis inHelicobacter pylori-colonized stomach: New clues for the pathogenesis ofH. pylori-related gastric inflammation. World Journal of Gastroenterology, 2014, 20, 639.	1.4	23
141	A functional role for Smad7 in sustaining colon cancer cell growth and survival. Cell Death and Disease, 2014, 5, e1073-e1073.	2.7	61
142	Analysis of the cytokine profile in the duodenal mucosa of refractory coeliac disease patients. Clinical Science, 2014, 126, 451-458.	1.8	31
143	An Overview of the Role of Innate Lymphoid Cells in Gut Infections and Inflammation. Mediators of Inflammation, 2014, 2014, 1-7.	1.4	21
144	Serum regenerating isletâ€derived 3â€alpha is a biomarker of mucosal enteropathies. Alimentary Pharmacology and Therapeutics, 2014, 40, 974-981.	1.9	23

#	Article	IF	Citations
145	IL-21 Is a Major Negative Regulator of IRF4-Dependent Lipolysis Affecting Tregs in Adipose Tissue and Systemic Insulin Sensitivity. Diabetes, 2014, 63, 2086-2096.	0.3	49
146	The impact of translational research on gastroenterology. Digestive and Liver Disease, 2014, 46, 293-294.	0.4	1
147	Preclinical Studies of a Specific PPARÎ³ Modulator in the Control of Skin Inflammation. Journal of Investigative Dermatology, 2014, 134, 1001-1011.	0.3	44
148	Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut. Mucosal Immunology, 2014, 7, 1467-1479.	2.7	75
149	Sampling of proximal and distal duodenal biopsies in the diagnosis and monitoring of celiac disease. Digestive and Liver Disease, 2014, 46, 323-329.	0.4	18
150	Plasma Cells in the Mucosa of Patients with Inflammatory Bowel Disease Produce Granzyme B and Possess Cytotoxic Activities. Journal of Immunology, 2014, 192, 6083-6091.	0.4	67
151	Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells. Carcinogenesis, 2014, 35, 1536-1546.	1.3	40
152	IL-21 as a therapeutic target in inflammatory disorders. Expert Opinion on Therapeutic Targets, 2014, 18, 1329-1338.	1.5	28
153	Targets for new immunomodulation strategies in inflammatory bowel disease. Autoimmunity Reviews, 2014, 13, 11-14.	2.5	34
154	Targeting Integrins and Adhesion Molecules to Combat Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 1885-1889.	0.9	7
155	Interleukinâ€21 in chronic inflammatory diseases. BioFactors, 2013, 39, 368-373.	2.6	23
156	The role of interleukin 17 in Crohnâ€™s disease-associated intestinal fibrosis. Fibrogenesis and Tissue Repair, 2013, 6, 13.	3.4	82
157	The Role of IL-21 in Chronic Inflammatory Skin Diseases. Current Dermatology Reports, 2013, 2, 11-17.	1.1	1
158	Th17 Cytokines in Inflammatory Bowel Diseases: Discerning the Good from the Bad. International Reviews of Immunology, 2013, 32, 526-533.	1.5	35
159	Local immune activity in acute coronary syndrome: oxLDL abrogates LPS-tolerance in mononuclear cells isolated from culprit lesion. International Journal of Cardiology, 2013, 169, 44-51.	0.8	5
160	IL-25 prevents and cures fulminant hepatitis in mice through a myeloid-derived suppressor cell-dependent mechanism. Hepatology, 2013, 58, 1436-1450.	3.6	45
161	Smad7 antisense oligonucleotide-based therapy for inflammatory bowel diseases. Digestive and Liver Disease, 2013, 45, 552-555.	0.4	14
162	<scp>H</scp>elicobacter pylori Infection Associates with a Mucosal Downregulation of Ghrelin, Negative Regulator of Th1â€Cell Responses. Helicobacter, 2013, 18, 406-412.	1.6	8

#	Article	IF	Citations
163	IL-15 positively regulates IL-21 production in celiac disease mucosa. Mucosal Immunology, 2013, 6, 244-255.	2.7	64
164	Association between â˜308 G/A TNF-Î±Polymorphism and Appendicular Skeletal Muscle Mass Index as a Marker of Sarcopenia in Normal Weight Obese Syndrome. Disease Markers, 2013, 35, 615-623.	0.6	41
165	The Dual Role of Smad7 in the Control of Cancer Growth and Metastasis. International Journal of Molecular Sciences, 2013, 14, 23774-23790.	1.8	76
166	Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Mesalazine in the Chemoprevention of Colorectal Cancer. International Journal of Molecular Sciences, 2013, 14, 17972-17985.	1.8	71
167	Role of T_H17 cytokines in the control of colorectal cancer. OncoImmunology, 2013, 2, e26617.	2.1	92
168	Investigational cytokine-targeted therapies for ulcerative colitis. Expert Opinion on Investigational Drugs, 2013, 22, 1123-1132.	1.9	2
169	Reduction of CD68+ Macrophages and Decreased IL-17 Expression in Intestinal Mucosa of Patients with Inflammatory Bowel Disease Strongly Correlate With Endoscopic Response and Mucosal Healing following Infliximab Therapy. Inflammatory Bowel Diseases, 2013, 19, 729-739.	0.9	62
170	Distinct Profiles of Effector Cytokines Mark the Different Phases of Crohnâ€™s Disease. PLoS ONE, 2013, 8, e54562.	1.1	86
171	The Dual Role of Inflammation in Colon Carcinogenesis. International Journal of Molecular Sciences, 2012, 13, 11071-11084.	1.8	77
172	Colorectal Cancer Chemoprevention by Mesalazine and Its Derivatives. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-6.	3.0	30
173	The aryl hydrocarbon receptor in inflammatory bowel disease. Current Opinion in Gastroenterology, 2012, 28, 310-313.	1.0	75
174	Th17-Related Cytokines in Inflammatory Bowel Diseases: Friends or Foes?. Current Molecular Medicine, 2012, 12, 592-597.	0.6	87
175	Interleukin-21 in Immune and Allergic Diseases. Inflammation and Allergy: Drug Targets, 2012, 11, 313-319.	1.8	13
176	2-Methoxy-5-amino-N-hydroxybenzamide, a derivative of mesalamine, inhibits colon cancer cell growth through cyclo-oxygenase-2-dependent and -independent mechanisms. Clinical Science, 2012, 123, 295-306.	1.8	1
177	A phase 1 openâ€label trial shows that smad7 antisense oligonucleotide (<scp>GED</scp>0301) does not increase the risk of small bowel strictures in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2012, 36, 850-857.	1.9	53
178	Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease. Molecular Therapy, 2012, 20, 870-876.	3.7	125
179	Reprogramming the Immune System in IBD. Digestive Diseases, 2012, 30, 392-395.	0.8	14
180	Tissue Inhibitor of Metalloproteinase-3 Regulates Inflammation in Human and Mouse Intestine. Gastroenterology, 2012, 143, 1277-1287.e4.	0.6	36

#	Article	IF	Citations
181	Role of Smad7 in inflammatory bowel diseases. World Journal of Gastroenterology, 2012, 18, 5664.	1.4	23
182	WhatÊ¼s the next best cytokine target in IBD?. Inflammatory Bowel Diseases, 2012, 18, 2180-2189.	0.9	27
183	Disruption of inflammatory signals by cytokineâ€targeted therapies for inflammatory bowel diseases. British Journal of Pharmacology, 2012, 165, 820-828.	2.7	12
184	Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. Inflammatory Bowel Diseases, 2012, 18, 449-459.	0.9	42
185	Th17-cytokine blockers as a new approach for treating inflammatory bowel disease. Annals of Medicine, 2011, 43, 172-178.	1.5	7
186	Regulation of Homeostasis and Inflammation in the Intestine. Gastroenterology, 2011, 140, 1768-1775.	0.6	233
187	Aryl Hydrocarbon Receptor-Induced Signals Up-regulate IL-22 Production and Inhibit Inflammation in the Gastrointestinal Tract. Gastroenterology, 2011, 141, 237-248.e1.	0.6	475
188	TH17 Cells and IL-23 in Gut Inflammation. , 2011, , 257-267.		0
189	Emerging immunological targets in inflammatory bowel disease. Current Opinion in Pharmacology, 2011, 11, 640-645.	1.7	59
190	Cytokine Therapies in Crohns Disease: Where are We Now and where should We Go?. Inflammation and Allergy: Drug Targets, 2011, 10, 47-53.	1.8	8
191	Interleukin-25 fails to activate STAT6 and induce alternatively activated macrophages. Immunology, 2011, 132, 66-77.	2.0	11
192	Psoriasis: from pathogenesis to novel therapeutic approaches. Clinical Science, 2011, 120, 1-11.	1.8	83
193	Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Medicine, 2011, 9, 122.	2.3	73
194	Smad7 Expression in T cells Prevents Colitis-Associated Cancer. Cancer Research, 2011, 71, 7423-7432.	0.4	56
195	Interleukin-25 production is differently regulated by TNF-Î± and TGF-Î²1 in the human gut. Mucosal Immunology, 2011, 4, 239-244.	2.7	44
196	Targeting interleukin-21 in inflammatory diseases. Expert Opinion on Therapeutic Targets, 2011, 15, 695-702.	1.5	31
197	2-Methoxy-5-Amino-N-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression. Molecular Cancer Therapeutics, 2011, 10, 1969-1981.	1.9	17
198	Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. Journal of Experimental Medicine, 2011, 208, 2279-2290.	4.2	126

#	Article	IF	Citations
199	IL-21 Promotes Skin Recruitment of CD4+ Cells and Drives IFN-Î³â€“Dependent Epidermal Hyperplasia. Journal of Immunology, 2011, 186, 5435-5442.	0.4	43
200	The opposing roles of IL-21 and TGFÎ²1 in chronic inflammatory bowel disease. Biochemical Society Transactions, 2011, 39, 1061-1066.	1.6	14
201	Intestinal inflammation and colorectal cancer: a double-edged sword?. World Journal of Gastroenterology, 2011, 17, 3092-100.	1.4	87
202	Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflammatory Bowel Diseases, 2010, 16, 1332-1339.	0.9	89
203	IL-23/IL-17 axis in IBD. Inflammatory Bowel Diseases, 2010, 16, 1808-1813.	0.9	221
204	Characterization of IL-17Aâ€“Producing Cells in Celiac Disease Mucosa. Journal of Immunology, 2010, 184, 2211-2218.	0.4	106
205	T-cell-directed therapies in inflammatory bowel diseases. Clinical Science, 2010, 118, 707-715.	1.8	54
206	Role of IL-21 in inflammatory bowel disease. Expert Review of Clinical Immunology, 2010, 6, 537-541.	1.3	20
207	Interleukin-21: A New Mediator of Inflammation in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.	3.0	28
208	IL-21 in the pathogenesis and treatment of skin diseases. Journal of Dermatological Science, 2010, 60, 61-66.	1.0	34
209	Inhibition of Colon Carcinogenesis by 2-Methoxy-5-Amino-N-Hydroxybenzamide, a Novel Derivative of Mesalamine. Gastroenterology, 2010, 138, 221-230.	0.6	16
210	Interleukin-25: A two-edged sword in the control of immune-inflammatory responses. Cytokine and Growth Factor Reviews, 2010, 21, 471-475.	3.2	39
211	Interleukin-21 triggers effector cell responses in the gut. World Journal of Gastroenterology, 2010, 16, 3638.	1.4	40
212	Differential regulation of interleukin 17 and interferon Â production in inflammatory bowel disease. Gut, 2009, 58, 1629-1636.	6.1	299
213	Pathogenic role of interleukin-21 in psoriasis. Cell Cycle, 2009, 8, 3629-3630.	1.3	12
214	Interleukin-23 and Th17 Cells in the Control of Gut Inflammation. Mediators of Inflammation, 2009, 2009, 1-7.	1.4	54
215	Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nature Medicine, 2009, 15, 1013-1015.	15.2	183
216	Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine and Growth Factor Reviews, 2009, 20, 185-191.	3.2	69

#	Article	IF	Citations
217	Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends in Pharmacological Sciences, 2009, 30, 441-447.	4.0	63
218	Smad7 Controls Resistance of Colitogenic T Cells to Regulatory T Cell-Mediated Suppression. Gastroenterology, 2009, 136, 1308-1316.e3.	0.6	147
219	Interleukin-25 Inhibits Interleukin-12 Production and Th1 Cell-Driven Inflammation in the Gut. Gastroenterology, 2009, 136, 2270-2279.	0.6	121
220	Transforming growth factor Â signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut, 2009, 58, 777-789.	6.1	179
221	Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinaseâ€“dependent induction of Socs-3. Blood, 2009, 113, 3512-3519.	0.6	57
222	Involvement of interleukin-15 and interleukin-21, two Î³-chain-related cytokines, in celiac disease. World Journal of Gastroenterology, 2009, 15, 4609.	1.4	27
223	Interleukin-21 in T cell-mediated diseases. Discovery Medicine, 2009, 8, 113-7.	0.5	11
224	ILâ€23â€mediated regulation of ILâ€17 production in Helicobacter pyloriâ€infected gastric mucosa. European Journal of Immunology, 2008, 38, 470-478.	1.6	145
225	Why are molecular mechanisms of immune activation important in IBD?. Inflammatory Bowel Diseases, 2008, 14, S106-S107.	0.9	2
226	Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochemical Pharmacology, 2008, 75, 668-676.	2.0	79
227	Regulation of Gut Inflammation and Th17 Cell Response by Interleukin-21. Gastroenterology, 2008, 134, 1038-1048.e2.	0.6	244
228	Th17 immune response in IBD: A new pathogenic mechanism. Journal of Crohn's and Colitis, 2008, 2, 291-295.	0.6	39
229	Blockade of transforming growth factor Â upregulates T-box transcription factor T-bet, and increases T helper cell type 1 cytokine and matrix metalloproteinase-3 production in the human gut mucosa. Gut, 2008, 57, 605-612.	6.1	83
230	Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends in Immunology, 2008, 29, 290-294.	2.9	86
231	IL-21 comes of age as a regulator of effector T cells in the gut. Mucosal Immunology, 2008, 1, 110-115.	2.7	36
232	Autocrine Regulation of IL-21 Production in Human T Lymphocytes. Journal of Immunology, 2008, 180, 1800-1807.	0.4	100
233	Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut, 2008, 57, 887-892.	6.1	150
234	Transcriptional and post-translational regulation of Flip, an inhibitor of Fas-mediated apoptosis, in human gut inflammation. Gut, 2008, 57, 1674-1680.	6.1	12

#	Article	IF	Citations
235	Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis, 2008, 29, 1258-1266.	1.3	30
236	TGF-Î²1 and Smad7 in the regulation of IBD. Mucosal Immunology, 2008, 1, S50-S53.	2.7	99
237	Why are molecular mechanisms of immune activation important in IBD?. Inflammatory Bowel Diseases, 2008, 14, S106-S107.	0.9	0
238	Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3Î±. Blood, 2008, 112, 3339-3347.	0.6	99
239	Molecular basis of the potential of mesalazine to prevent colorectal cancer. World Journal of Gastroenterology, 2008, 14, 4434.	1.4	31
240	Interleukin-21 (IL-21) Controls Inflammatory Pathways in the Gut. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2007, 7, 288-291.	0.6	22
241	Role of Interleukin-21 in Inflammation and Allergy. Inflammation and Allergy: Drug Targets, 2007, 6, 63-68.	1.8	19
242	IL-21 Is Highly Produced in Helicobacter pylori-Infected Gastric Mucosa and Promotes Gelatinases Synthesis. Journal of Immunology, 2007, 178, 5957-5965.	0.4	94
243	IL-21 Counteracts the Regulatory T Cell-Mediated Suppression of Human CD4+ T Lymphocytes. Journal of Immunology, 2007, 178, 732-739.	0.4	256
244	A Functional Role for Interleukin-21 in Promoting the Synthesis of the T-Cell Chemoattractant, MIP-3Î±, by Gut Epithelial Cells. Gastroenterology, 2007, 132, 166-175.	0.6	152
245	Functional Modulation of Crohnâ€™s Disease Myofibroblasts by Anti-Tumor Necrosis Factor Antibodies. Gastroenterology, 2007, 133, 137-149.	0.6	145
246	Evidence for the Role of Interferon-alfa Production by Dendritic Cells in the Th1 Response in Celiac Disease. Gastroenterology, 2007, 133, 1175-1187.	0.6	119
247	New players in the cytokine orchestra of inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 1419-1423.	0.9	67
248	ILâ€21 regulates experimental colitis by modulating the balance between T_{reg} and Th17 cells. European Journal of Immunology, 2007, 37, 3155-3163.	1.6	149
249	Control of mucosal immune responses by transforming growth factor-Î². , 2007, , 29-34.		0
250	Contraindications for whole body vibration training: a case of nephrolitiasis. Journal of Sports Medicine and Physical Fitness, 2007, 47, 443-5.	0.4	3
251	A Functional Role of Flip in Conferring Resistance of Crohnâ€™s Disease Lamina Propria Lymphocytes to FAS-Mediated Apoptosis. Gastroenterology, 2006, 130, 389-397.	0.6	27
252	Inhibition of Smad7 With a Specific Antisense Oligonucleotide Facilitates TGF-Î²1â€“Mediated Suppression of Colitis. Gastroenterology, 2006, 131, 1786-1798.	0.6	182

#	Article	IF	Citations
253	Bacteria and mucosal immunity. Digestive and Liver Disease, 2006, 38, S256-S260.	0.4	17
254	5-Aminosalicylic acid enhances anchorage-independent colorectal cancer cell death. European Journal of Cancer, 2006, 42, 2609-2616.	1.3	23
255	Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut, 2006, 55, 1774-1780.	6.1	159
256	Interleukin-12 and Th1 immune response in Crohnâ€™s disease: Pathogenetic relevance and therapeutic inplication. World Journal of Gastroenterology, 2006, 12, 5606.	1.4	117
257	The Smad System. Inflammatory Bowel Diseases, 2006, 12, S10.	0.9	0
258	New mediators of immunity and inflammation in inflammatory bowel disease. Current Opinion in Gastroenterology, 2006, 22, 361-364.	1.0	82
259	Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death and Differentiation, 2006, 13, 202-211.	5.0	41
260	Overview of Role of the Immune System in the Pathogenesis of Inflammatory Bowel Disease. Advances in Experimental Medicine and Biology, 2006, 579, 98-107.	0.8	15
261	Immunity, Inflammation, and Allergy in the Gut. Science, 2005, 307, 1920-1925.	6.0	977
262	Interleukin-21 enhances T-helper cell type I signaling and interferon-Î³ production in Crohnâ€™s disease. Gastroenterology, 2005, 128, 687-694.	0.6	283
263	Post-transcriptional Regulation of Smad7 in the Gut of Patients With Inflammatory Bowel Disease. Gastroenterology, 2005, 129, 1420-1429.	0.6	101
264	Regulation of the T helper cell type 1 transcription factor T-bet in coeliac disease mucosa. Gut, 2004, 53, 1090-1095.	6.1	85
265	A Failure of Transforming Growth Factor-Î²1 Negative Regulation Maintains Sustained NF-ÎºB Activation in Gut Inflammation. Journal of Biological Chemistry, 2004, 279, 3925-3932.	1.6	133
266	Extracellular Signal-Regulated Protein Kinase Mediates Interleukin 17 (IL-17)-Induced IL-8 Secretion in Helicobacter pylori -Infected Human Gastric Epithelial Cells. Infection and Immunity, 2004, 72, 5019-5026.	1.0	51
267	Cutting Edge: TGF-Î² Induces a Regulatory Phenotype in CD4+CD25â^' T Cells through Foxp3 Induction and Down-Regulation of Smad7. Journal of Immunology, 2004, 172, 5149-5153.	0.4	1,060
268	Induction and regulation of Smad7 in the gastric mucosa of patients with Helicobacter pylori infection. Gastroenterology, 2004, 126, 674-682.	0.6	62
269	Smad7 in TGF-Î²-mediated negative regulation of gut inflammation. Trends in Immunology, 2004, 25, 513-517.	2.9	133
270	Constitutive Activation of the Signal Transducer and Activator of Transcription Pathway in Celiac Disease Lesions. American Journal of Pathology, 2003, 162, 1845-1855.	1.9	42

#	Article	IF	Citations
271	Activated STAT4 and a Functional Role for IL-12 in Human Peyerâ€™s Patches. Journal of Immunology, 2003, 170, 300-307.	0.4	18
272	Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut, 2002, 50, 186-190.	6.1	118
273	IL-12 and Th1 immune responses in human Peyer's patches. Trends in Immunology, 2001, 22, 244-247.	2.9	70
274	Interferon-Î± drives T cell-mediated immunopathology in the intestine. European Journal of Immunology, 2001, 31, 2247-2255.	1.6	78
275	Role of interferon alpha in promoting T helper cell type 1 responses in the small intestine in coeliac disease. Gut, 2001, 48, 425-429.	6.1	129
276	Blocking Smad7 restores TGF-Î²1 signaling in chronic inflammatory bowel disease. Journal of Clinical Investigation, 2001, 108, 601-609.	3.9	517
277	Up-Regulation of IL-17 Is Associated with Bioactive IL-8 Expression inHelicobacter pylori-Infected Human Gastric Mucosa. Journal of Immunology, 2000, 165, 5332-5337.	0.4	250
278	Human Peyerâ€™s Patch T Cells Are Sensitized to Dietary Antigen and Display a Th Cell Type 1 Cytokine Profile. Journal of Immunology, 2000, 165, 5315-5321.	0.4	86
279	Manipulation of cytokines in the management of patients with inflammatory bowel disease. Annals of Medicine, 2000, 32, 552-560.	1.5	45
280	Up-Regulation of the IL-12 Receptor Î²2 Chain in Crohnâ€™s Disease. Journal of Immunology, 2000, 165, 7234-7239.	0.4	127
281	Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut, 2000, 47, 57-62.	6.1	135
282	IL-4 hyporesponsiveness of Crohn's disease mucosal T lymphocytes: a response of polarised Th1 cells?. Digestive and Liver Disease, 2000, 32, 495-497.	0.4	5
283	Interferon-gamma (IFN-Î³) and prostaglandin E2 (PGE2) regulate differently IL-12 production in human intestinal lamina propria mononuclear cells (LPMC). Clinical and Experimental Immunology, 1999, 117, 469-475.	1.1	28
284	Changes in the mucosal expression of interleukin 15 inHelicobacter pylori-associated gastritis. FEMS Immunology and Medical Microbiology, 1999, 24, 233-238.	2.7	6
285	Enhancing lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology, 1999, 117, 1069-1077.	0.6	96
286	Bioactive IL-18 expression is up-regulated in Crohn's disease. Journal of Immunology, 1999, 163, 143-7.	0.4	267
287	Interleukin 12 and Th1 responses in inflammatory bowel disease. Gut, 1998, 43, 735-736.	6.1	84
288	Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7. Gut, 1998, 43, 620-628.	6.1	48

#	Article	IF	Citations
289	Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology, 1997, 112, 1169-1178.	0.6	533
290	Targeting IL-34/MCSF-1R Axis in Colon Cancer. Frontiers in Immunology, 0, 13, .	2.2	6